The division will be renamed International Health Science but will retain its current corporate structure and managerial organisation.
The group will use its combined expertise and shared common values to strengthen critical relationships and develop innovative products, validated through scientific testing.
In addition, the acquisition opens up new growth opportunities in healthcare, according to Giellepi founder and CEO Carlo Terruzzi.
Giellepi has so far achieved exceptional results from an organisational and economic point of view, he says, but maintains “even more extraordinary results” will be achieved as a result of the new business structure.
“Giellepi – totally focused on the Raw Materials destined for the Food Supplements industry – will have more resources to invest in its business, thus promoting a growth process also for external lines; on the other, Biofarma Group is the ideal partner for the IHS division in a new phase of growth, in an increasingly competitive global context,” he adds. .
Biofarma CEO, Maurizio Castorina, will sit on the board of directors, along with other managers from the group, while Terruzzi will stay on as CEO and continue to play an active role in the company’s development.
Castorina asserts that the acquisition will “allow Biofarma Group to strengthen its R&D and regulatory teams, to achieve the stated goal of technological and innovation leadership at European level”.
Giellepi will continue to operate in the raw materials market, organising the distribution of branded ingredients in a more effective and efficient way, while maintaining its investment in innovation and proprietary clinical studies.
Milan-based Giellepi Ingredients Division develops raw materials in the nutraceutical, pharmaceutical and cosmetic sectors for use in food supplements, cosmetics, functional foods, and medical purposes, including a range of antioxidants, botanical extracts, prebiotics, flavonoids, and vitamins.
As well as supplying ingredients to industry partners, Giellepi develops ready-to-market products, including for immune support, women’s health, and treatment for gastro-intestinal and metabolic / cardio issues.
The company has its own 1,500m2 research and development facilities, with laboratories for stability testing and pre-clinical and clinical trials.
In contrast, Biopharma Group’s manufacturing and logistics activities span 100,000m2 with four sites in Northern Italy (Mereto, San Pietro Viminaro, Gallarate and Cusano Milanino), including three R&D labs.
It offers both third party products and 70 ready-to-market products, as well as a range of probiotic and well-being food supplements in capsule, tablet (including tablets with multi-layers), liquid, and powder formats.
The group’s ready-to-market therapeutic products target prediabetes, non-alcoholic fatty liver disease, pre-hypertension, sleep disorders, pre-depression, hyperuricaemia, and prostate enlargement.
Biopharma also has a research programme for sustainable cosmetic formulations and packaging, including solid shampoo, waterless formulations, and environmental-friendly packaging.